Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Hochster

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2009
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology GroupElizabeth Poplin, Yang Feng, Jordan Berlin, et al.
Cancer Chemotherapy and Pharmacology|May 23, 2007
A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancerRamesh K Ramanathan, Joel Picus, Haralambos Raftopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2008
Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II studyPeter S Kozuch, Caio Max Rocha-Lima, Tomislav Dragovich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trialsHendrik-Tobias Arkenau, Dirk Arnold, Jim Cassidy, et al.
Clinical Colorectal Cancer|August 16, 2005
Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group studyCynthia G Leichman, Jacqueline K Benedetti, Mark M Zalupski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2004
Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancerNancy Kemeny, Carlos A Garay, Jayne Gurtler, et al.
Journal of Gastrointestinal Oncology|July 11, 2024
A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancerNipun Verma, Kimberly L Johung, Jeremy Kortmansky, et al.
Oncology & Hematology Review|August 25, 2020
The Evolving Role of Radiotherapy in Locally Advanced Rectal Cancer and the Potential for Nonoperative ManagementKarishma Khullar, Nell Maloney Patel, Cristan Anderson, et al.
Annals of Surgical Oncology|July 20, 2011
Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinomaDeirdre J Cohen, Elliot Newman, Syma Iqbal, et al.
Cancer Chemotherapy and Pharmacology|February 18, 2009
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumorsAnna C Pavlick, Jennifer Wu, John Roberts, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2009
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology GroupElizabeth Poplin, Yang Feng, Jordan Berlin, et al.
Cancer Chemotherapy and Pharmacology|May 23, 2007
A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancerRamesh K Ramanathan, Joel Picus, Haralambos Raftopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2008
Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II studyPeter S Kozuch, Caio Max Rocha-Lima, Tomislav Dragovich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trialsHendrik-Tobias Arkenau, Dirk Arnold, Jim Cassidy, et al.
Clinical Colorectal Cancer|August 16, 2005
Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group studyCynthia G Leichman, Jacqueline K Benedetti, Mark M Zalupski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2004
Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancerNancy Kemeny, Carlos A Garay, Jayne Gurtler, et al.
Journal of Gastrointestinal Oncology|July 11, 2024
A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancerNipun Verma, Kimberly L Johung, Jeremy Kortmansky, et al.
Oncology & Hematology Review|August 25, 2020
The Evolving Role of Radiotherapy in Locally Advanced Rectal Cancer and the Potential for Nonoperative ManagementKarishma Khullar, Nell Maloney Patel, Cristan Anderson, et al.
Annals of Surgical Oncology|July 20, 2011
Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinomaDeirdre J Cohen, Elliot Newman, Syma Iqbal, et al.
Cancer Chemotherapy and Pharmacology|February 18, 2009
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumorsAnna C Pavlick, Jennifer Wu, John Roberts, et al.
Pageof 6